12 Units of Semaglutide: Understanding the Measurement

Step 1: Where the phrase "12 units" comes from

The confusion usually starts with content originating in the United States, where compounded semaglutide (produced by unlicensed compounding pharmacies) has been sold in vials alongside insulin syringes. On a U-100 syringe (the standard type used for insulin), 1 unit equals 0.01 ml. Twelve units therefore equals 0.12 ml. If a vial contains, say, 5 mg of semaglutide per ml, then 0.12 ml would deliver 0.6 mg of semaglutide.

That arithmetic only works if you know the concentration of the vial, and concentrations vary between batches and sellers. A small error in drawing up 12 versus 20 units could mean a significant overdose or underdose, depending on your vial's concentration. This is precisely why licensed medicines move away from this approach. It introduces unnecessary risk that a pre-filled pen eliminates entirely.

In the UK, the MHRA has not approved compounded semaglutide for weight management, and any product asking you to draw up units from a vial sits outside the licensed supply chain. The MHRA's Yellow Card scheme exists partly so patients can report suspect products, including anything sold without a valid prescription from a verified prescriber.

Step 2: How the licensed Wegovy dose ladder actually works

Licensed Wegovy in the UK is a once-weekly subcutaneous injection delivered via a pre-filled, pre-set pen. You press the pen against your skin, press the button, and the correct volume is injected automatically. No measuring. No syringes.

The dose escalation pathway starts at 0.25 mg weekly, then moves through 0.5 mg, 1.0 mg, 1.7 mg, and up to 2.4 mg as the standard maintenance dose, or 7.2 mg with the higher-dose pen approved by the MHRA in April 2026. Each step is managed by your prescriber, typically at roughly four-weekly intervals, based on how you are tolerating treatment. The full Wegovy overview covers the escalation schedule and what to expect at each stage.

If you are curious how specific volumes translate between measurement systems (for example, how 0.5 mg relates to millilitres at a given concentration) our semaglutide ml-to-units converter guide walks through the maths clearly. But for licensed Wegovy pens, that calculation is done for you before the pen ever reaches you.

Step 3: Why the distinction between units and doses matters for your safety

The NHS guidance on semaglutide is clear that dose changes should only happen under clinical supervision. A prescriber monitors for side effects (nausea, vomiting, and gastrointestinal discomfort are common, particularly after each increase) and adjusts the schedule accordingly. Moving through the dose steps faster than recommended, or guessing at a unit-based equivalent, removes that safety net.

There is also a supply-chain issue. Large seizures of fake weight-loss pens have been made by UK enforcement bodies, and some counterfeits have contained entirely different substances. Vials sold with syringes and unit-based instructions, often through social media or unverifiable websites, are among the highest-risk categories. A pharmacy you can check on the GPhC register (and that sources medicines through the licensed UK supply chain) removes that risk by design.

For context on how Wegovy performs at its therapeutic doses, the evidence on Wegovy's effectiveness covers trial data including STEP 1, where participants at the 2.4 mg maintenance dose achieved around 15% average weight reduction over 68 weeks, as published in the New England Journal of Medicine. Those results came from a licensed, controlled dose, not from a drawn-up approximation.

Step 4: What to do if you are looking for a legitimate route to semaglutide in the UK

The path is straightforward. A free online consultation with a GPhC-registered prescriber establishes whether Wegovy is appropriate for your circumstances, your BMI, medical history, any current medications. If approved, treatment is dispensed from a GPhC-registered pharmacy and delivered to your door. No syringe required, ever.

Eligibility broadly covers adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes. Lower thresholds apply for some ethnic backgrounds under UK guidance. But BMI is a starting point, not the whole picture; the prescriber's assessment looks at the full clinical context.

If you are weighing up options or want to understand what private treatment involves before committing, the weight-loss treatment overview is a sensible place to start. Cost is a fair question too, the Wegovy price comparison guide sets out what to expect from private providers and what a transparent price should include. Worth reading before you decide.

Our prescribers review consultations the same day, a real clinician reads your answers, not an automated system. If you want to understand how starting at 5 units relates to the lowest therapeutic dose before your first consultation, that guide explains the numbers in plain terms. If you order before midday on a working day and are clinically approved, treatment is dispatched that day and arrives with DPD the next working day, in plain packaging. That timing works for a lot of people who want certainty rather than an open-ended wait.